Stem cells take on ankylosing spondylitis: first human trial begins
NCT ID NCT07632599
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether stem cells from donated bone marrow (CG-BM1) are safe for people with ankylosing spondylitis, a chronic inflammatory arthritis. Forty adults aged 18 to 40 will receive either the stem cells or a placebo by IV once a week for four weeks. The study will monitor side effects and look for signs of improvement in pain, stiffness, and function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allogeneic human bone marrow mesenchymal stem cells (CG-BM1)
What this could lead to
If successful, this could point toward a new treatment option for ankylosing spondylitis that reduces inflammation and improves symptoms.
What could go wrong
This is a very early Phase 1 trial with only 40 participants, so safety and effectiveness are not yet proven. The stem cells may cause side effects or not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Eighth Affiliated Hospital, Sun Yat-sen University
Shenzhen, Guangdong, 518033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••